Lumexa Imaging (LMRI) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $13.00 from $9.00 | Aug 28, 2026 |
| Barclays | Maintained | Overweight | $9.00 from $15.00 | May 20, 2026 |
| Barclays | Maintained | Overweight | $15.00 from $23.00 | Apr 14, 2026 |
| Raymond James | Upgraded | Outperform → Strong Buy | $23.00 | Feb 9, 2026 |
| William Blair | Initiated Coverage | Outperform | — | Jan 5, 2026 |
| Jefferies | Initiated Coverage | Buy | $23.00 | Jan 5, 2026 |
| Wells Fargo | Initiated Coverage | Overweight | $22.00 | Jan 5, 2026 |
| Barclays | Initiated Coverage | Overweight | $23.00 | Jan 5, 2026 |
| Raymond James | Initiated Coverage | Outperform | $23.00 | Jan 5, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $23.00 | Jan 5, 2026 |
| Deutsche Bank | Initiated Coverage | Buy | $22.00 | Jan 5, 2026 |
Frequently asked questions
Is LMRI a buy, sell, or hold?
Analysts covering Lumexa Imaging currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on LMRI?
On Aug 28, 2026, Barclays maintained Lumexa Imaging at Overweight with a price target of $13.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.